Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Post by Goldnboy1on Aug 02, 2022 6:22pm
245 Views
Post# 34866866

$6,000,000,000 Target!!

$6,000,000,000 Target!!

Abbvie's Rova-T has had over $6B invested in it.

Rova-T failed in final stage clinical trials due to Off Target Toxicity. 

The patents $APC is just being issued will allow them to get Rova-T back to the clinic.

Due to the advanced state of Rova-T. This would mean a fast track to Final stage trials. For this the $APC ADC would be licenced or a joint development agreement signed.

When Trillium signed their joint development agreement with Pfizer to go to clinic. Their stock went from $0.30 to $1.50 in a matter of a few months. Then the Ofizer raise was announced.

At anytime a major like AbbVie or Pfizer could do the same thing here. There will always be a period where the buy up the market before they fund it. I believe this final quarter of 2022 will be the last quarter to buy $apc as a penny stock. 

One of $APC's patents have been dubbed by the US patent office as superior to a patent owned by Pfizer. Pfizer acquired this patent in 2009. But they have failed to commercialize it. 

$APC's patent runs circles around theirs. If they already care enough about this market to spend tens of millions on an inferior patent a decade ago. Just imagine what they might pay for the answer they are looking for today!

The majors are coming!! Long and strong!!

<< Previous
Bullboard Posts
Next >>